Status:
COMPLETED
Almitrine and COVID-19 Related Hypoxemia
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
COVID-19
Hypoxic Respiratory Failure
Eligibility:
All Genders
18+ years
Brief Summary
In severe COVID-19 pulmonary failure, the profound hypoxemia is mainly related to pulmonary vasodilation with altered hypoxic pulmonary vasoconstriction (HPV). Besides prone positioning, other non-ven...
Detailed Description
The clinical presentation of COVID-19 disease is heterogenous, ranging from no symptoms to severe acute respiratory failure (ARF), which may have a poor prognosis. A severe hypoxemia is associated wit...
Eligibility Criteria
Inclusion
- Inclusion Criteria :
- a positive RT- PCR,
- a highly suggestive thoracic CTScan, and
- a severe hypoxemia leading to intubation for less than 3 days
- mechanically ventilated at FiO2 1 with a severe intrapulmonary shunt during their early phase
- Group : patient who has been treated with almitrine (4 mcg/kg/min iv almitrine bismesylate (Vectarion®, Servier Laboratory, France) then 12 mcg/kg/min infusion rate) during their hospital treatment.
- Control group : Matched COVID-19 patients, on gender, age, BMI and duration of mechanical ventilation, with serial measurements corresponding to the duration of almitrine testing (8 hours), with same inclusion and exclusion criteria.
- Exclusion Criteria:
- the presence of an acute cor-pulmonale on the trans-thoracic 2D Echo-Doppler
- abnormal liver function tests
- hyperlactatemia
Exclusion
Key Trial Info
Start Date :
March 20 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 25 2020
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT04380727
Start Date
March 20 2020
End Date
April 25 2020
Last Update
July 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Universitaire NANCY
Vandœuvre-lès-Nancy, France, 54511